Eledon Pharma reports 100% insulin independence in 12‑patient Type 1 diabetes islet trial
Eledon Pharmaceuticals announced that all 12 participants in its investigator‑initiated islet transplantation study achieved insulin independence, with 10 patients beyond four weeks post‑transplant showing HbA1c below 6.0%. The trial used the anti‑CD40L antibody tegoprubart and reported no graft rejection or major adverse events, highlighting a potential functional cure for Type 1 diabetes.